A recent study explores the long-term safety and efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. Do you know the role TYK2 plays in...
A recent study investigates the use of apremilast for pediatric patients with moderate-to-severe plaque psoriasis. Can you identify one of the key benefits of this treatment option for children? Take our...
When managing patients with psoriatic arthritis who do not respond to tumor necrosis factor inhibitors, clinicians must consider several factors before changing their treatment. Think you know what they...
According to the National Psoriasis Foundation Medical Board, what diet is strongly recommended for patients with psoriasis with overweight and obesity?
A recent study revealed that pregnant patients with psoriatic diseases have an increased risk of adverse maternal conditions and events, including Cesarean delivery, preterm birth, (pre)eclampsia,...
